Sorafenib kills liver cancer cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids via the ATP-AMPK-mTOR-SREBP1 signaling pathway.
Liu G, Kuang S, Cao R, Wang J, Peng Q, Sun C.
Liu G, et al. Among authors: kuang s.
FASEB J. 2019 Sep;33(9):10089-10103. doi: 10.1096/fj.201802619RR. Epub 2019 Jun 14.
FASEB J. 2019.
PMID: 31199678
These effects were partly abolished in the presence of compound C (an AMPK inhibitor) and ATP and adenosine, and SREBP1c overexpression also could be resistant to the effects of sorafenib, suggesting that the sorafenib-induced reduction in cell viability was mediated by the ATP-A …
These effects were partly abolished in the presence of compound C (an AMPK inhibitor) and ATP and adenosine, and SREBP1c overexpression also …